Staten Biotech exercises option to develop argenx antibody for dyslipidemia

March 6, 2017 News BioVox

Ghent-based antibody developer argenx has announced that Staten Biotech has exercised its exclusive option to license ARGX-116, an anti-ApoC3 SIMPLE AntibodyTM with therapeutic potential in dyslipidemia. This collaboration is the latest to stem from the argenx Innovative Access Program. 

“The discovery of ARGX-116 is truly one of collaboration, utilizing Staten’s unique expertise in dyslipidemia and our novel SIMPLE AntibodyTM platform to develop an antagonizing antibody against ApoC3, a target involved in triglyceride metabolism,” commented Tim Van Hauwermeiren, Chief Executive Officer of argenx. “We are highly encouraged by Staten’s decision to pursue further development of this exciting molecule and recognize that strategic collaborations like this one are a fundamental pillar of our mission allowing us to be a leader in developing therapeutic antibodies.”

argenx began its collaboration with Staten Biotech in 2015 as part of a research collaboration through its Innovative Access Program. Under the terms of the agreement, Staten will be responsible for additional development of ARGX-116, and argenx is eligible to receive a double-digit portion on income related to the product. Additional financial details of the collaboration have not been disclosed.

More news on Argenx

Avatar photo

With a local focus and global reach, BioVox shares insights into the Belgian life sciences ecosystem with an ever-growing global community. BioVox is a non-profit project: we are able to provide our community with free, quality content because of the generous support of Turnstone Communications and its clients. Our articles bring you hidden opportunities and exclusive insights into the latest research and industry trends!

All posts